Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Published:2009-07 Issue:7 Volume:20 Page:1264-1269
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sternberg C.N.,Dumez H.,Van Poppel H.,Skoneczna I.,Sella A.,Daugaard G.,Gil T.,Graham J.,Carpentier P.,Calabro F.,Collette L.,Lacombe D.

Funder

Genta Incorporated and Sanofi-Aventis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/7/1264/987324/mdn784.pdf

Reference17 articles.

1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Current indications for chemotherapy in prostate cancer patients;Calabrò;Eur Urol,2007

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

5. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides;Gleave;Urology,1999

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

2. Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer;The Prostate;2024-03-27

3. Small RNAs in Cancer Therapy;Interdisciplinary Cancer Research;2024

4. Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo;International Journal of Molecular Sciences;2023-09-25

5. Research progress on non-protein-targeted drugs for cancer therapy;Journal of Experimental & Clinical Cancer Research;2023-03-14